Skip to main content
Premium Trial:

Request an Annual Quote

Immusol's First Genomics Contract Is With Pfizer

Premium

SAN DIEGO--Privately held biopharmaceutical company Immusol announced its first genomics-based research collaboration with Pfizer to validate new therapeutic targets in the Pfizer drug discovery pipeline. A 1995 collaboration between the two firms to develop a gene therapy for the treatment of HIV will not be renewed, Immusol also announced. Instead, Immusol will continue to develop the HIV therapy in collaboration with Flossie Wong-Staal's laboratory at the University of California San Diego.

Under the terms of the new agreement, Pfizer will provide candidate gene target sequence information to Immusol for the design of specific ribozymes to each target. Immusol will deliver the ribozymes to mammalian cells, thereby generating an in vivo model to measure the loss of each selected target gene product and evaluate its function in disease. Financial terms were not disclosed.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.